133 related articles for article (PubMed ID: 29139250)
21. [32 546 intensive hospital monitoring cases of Shuxuetong injection].
Jiang JJ; Xie YM; Zhang Y; Yang ZX; Yi DH
Zhongguo Zhong Yao Za Zhi; 2016 Oct; 41(20):3852-3858. PubMed ID: 28929666
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation on safety of puerarin injection in clinical use].
Xie XS; Dong YZ; Mu DP; Pan XL; Zhang FY
Zhongguo Zhong Yao Za Zhi; 2018 Oct; 43(19):3956-3961. PubMed ID: 30453723
[TBL] [Abstract][Full Text] [Related]
23. [Protocol of intensive hospital monitoring with long follow up and large sample: Diemailing Kudiezi injection as example].
Liao X; Xie YM; Wang GQ
Zhongguo Zhong Yao Za Zhi; 2016 Dec; 41(24):4494-4499. PubMed ID: 28936829
[TBL] [Abstract][Full Text] [Related]
24. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
Yang W; Xiang YY; Xie YM; Shen H
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
[TBL] [Abstract][Full Text] [Related]
26. [Risk control system construction of Shenfu injection].
Tian DL; Li K; Jiang JJ; Zhu YN
Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2814-7. PubMed ID: 23285942
[TBL] [Abstract][Full Text] [Related]
27. [Expert consensus on the design and implementation of clinical safety centralized monitoring study of Chinese medical injection].
Zhang JH; Ren JT; Hu JQ; Xie YM; Song HB; Zhu MJ; Gao R; Wang Z; Zheng WK; Li XL; Jiang M; Huang YH; Lu F; He LY; Lian WX; Yang ZQ; Yuan WA; Hu SY; Wang BH; Wang WL; Ren DQ; Zhang BL; ;
Zhongguo Zhong Yao Za Zhi; 2017 Jan; 42(1):6-9. PubMed ID: 28945018
[TBL] [Abstract][Full Text] [Related]
28. [Post-marketed re-evaluation of fleabane injection and Dengzhan Shengmai capsule study on treatment in patients with ischemic stroke].
Wei X; Ye X; Xie Y; Zou Y; Zhao X; Han J; Wang X; Ma Y; Bi Q; Xie Q; Zhao J; Cao X; Chen H; Wang S; Yan R; Han Z; Yi D; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2789-92. PubMed ID: 22292366
[TBL] [Abstract][Full Text] [Related]
29. [Study of post marketing safety reevaluation of shenqi fuzheng injection].
Ai QH; Li YY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3633-6. PubMed ID: 25532410
[TBL] [Abstract][Full Text] [Related]
30. Adverse events to Houttuynia injection: A systematic review.
Wang L; Cui X; Cheng L; Yuan Q; Li T; Li Y; Deng S; Shang H; Bian Z
J Evid Based Med; 2010 Aug; 3(3):168-76. PubMed ID: 21349062
[TBL] [Abstract][Full Text] [Related]
31. Adverse drug reactions of Shenmai injection: a systematic review.
Zhang L; Hu J; Xiao L; Zhang Y; Zhao W; Zheng W; Shang H
J Evid Based Med; 2010 Aug; 3(3):177-82. PubMed ID: 21349063
[TBL] [Abstract][Full Text] [Related]
32. [Systematic analysis on clinical safety of Shuxuetong injection].
Guo XF; Wen ZH; Xie YM; Liu SN; Li ZY; Chen DC
Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2782-5. PubMed ID: 23285933
[TBL] [Abstract][Full Text] [Related]
33. Postmarketing Safety Surveillance and Reevaluation of Danhong Injection: Clinical Study of 30888 Cases.
Li XL; Tang JF; Li WX; Li CX; Zhao T; Zhao BC; Wang Y; Zhang H; Chen XF; Xu T; Zhu MJ
Evid Based Complement Alternat Med; 2015; 2015():610846. PubMed ID: 26508981
[TBL] [Abstract][Full Text] [Related]
34. [Discussion on establishment of quality control system for intensive hospital monitoring on traditional Chinese medicine injections].
Jiang JJ; Xie YM
Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2689-91. PubMed ID: 23285909
[TBL] [Abstract][Full Text] [Related]
35. [Post-marketing study on clinical safety of ginkgo diterpene lactone meglumine injection in 6 300 patients with ischemic stroke].
Zhou L; Gao Y; Lai XX; Xu TS; Yu M; Wang Y; Zhao JJ; Tan ZH
Zhongguo Zhong Yao Za Zhi; 2017 Dec; 42(24):4744-4749. PubMed ID: 29493141
[TBL] [Abstract][Full Text] [Related]
36. [Rationality analysis of clinical application of Danhong injection in affiliated hospital of Nanjing university of Chinese medicine from 2013 to 2014].
Zhang Q; Ju WZ; Guo JM; Li JP; Tan XY; Wang XX; Zhao BC; Tang ZS; Duan JA
Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(4):748-754. PubMed ID: 28871705
[TBL] [Abstract][Full Text] [Related]
37. [Systematic review on safety of sofren injection].
Que Y; Xie YM; Liao X; Zhang YL
Zhongguo Zhong Yao Za Zhi; 2016 Oct; 41(20):3866-3874. PubMed ID: 28929668
[TBL] [Abstract][Full Text] [Related]
38. [Investigation of clinical practice and side effects of Shenfu injection].
Fu YK; Xie YM
Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2796-9. PubMed ID: 23285937
[TBL] [Abstract][Full Text] [Related]
39. [Preliminary study on general safe medication regularity of Chinese patent orthopedic medicines based on adverse reaction/event literature analysis].
Wang YG; Shi XY; Jin R; Li HY; Kong XW; Qiao YJ
Zhongguo Zhong Yao Za Zhi; 2015 Mar; 40(6):1192-7. PubMed ID: 26226769
[TBL] [Abstract][Full Text] [Related]
40. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
